Buy & Sell C.H. Robinson Worldwide, Inc. (CHRW) – C.H. Robinson Worldwide, Inc. Price Today
Aura AI Summary
Key Stats
- $20.97BMarket Cap
- IndustrialsSector
- -17.35%3M Drawdown
- $22.45BEnterprise Value
- 1.42%Dividend Yield
- 30 daysTypical Hold Time
C.H. Robinson Worldwide, Inc. (CHRW) is currently valued at a market capitalization of $20.97B, with an enterprise value of $22.45B. Over the past 52 weeks, C.H. Robinson Worldwide, Inc. has traded between a low of $92.63 and a high of $200.59, highlighting its annual price range. Over the past three months, C.H. Robinson Worldwide, Inc. has recorded a drawdown of -17.35%, reflecting recent price volatility. C.H. Robinson Worldwide, Inc. offers a dividend yield of 1.42%, with the most recent dividend of $0.63 paid on 06 Mar 26. On average, investors hold C.H. Robinson Worldwide, Inc. for approximately 30 days, indicating typical investor behavior on the platform.
About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Most Recent News
Emerson Electric partners with Aramco to develop advanced corrosion monitoring systems.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...

Modern inflation differs from the 1970s, driven by supply issues, not wage-price spirals.
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...

Atea Pharma shows low drug interaction risk for new Hepatitis C treatment and promising Hepatitis E antiviral data.
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
